🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07179211
Active, not recruiting Observational

Peripheral Artery Disease in Regular Hemodialysis Patients

NCT07179211 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-07-13
Last updated
2025-09-17

Condition(s) studied

Chronic Kidney Disease

Study summary

Recent studies have reinforced the association between high NLR and PAD in hemodialysis patients. This highlights the need for further studies to confirm its predictive value and determine optimal cut-off thresholds tailored to local patient populations. Accordingly, the present study aims to investigate the relationship between NLR and the presence of PAD in patients undergoing regular hemodialysis. By establishing this association in a well-defined population, we hope to provide evidence that supports the use of NLR as a simple, cost-effective tool for PAD risk stratification and early intervention

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients aged ≥18 years. * Undergoing maintenance hemodialysis for at least 3 months (thrice weekly) * Able to provide informed consent. * Willing to undergo clinical and laboratory evaluations, including peripheral vascular assesment Exclusion Criteria: * Active infection or sepsis at the time of evaluation .\* Patients who have a sedimentation rate of more than 60 mm/hour \*. Known autoimmune or hematologic disorders that may influence leukocyte count. * Current use of immunosuppressive therapy, corticosteroids, or chemotherapy.5. History of malignancy.6. Patients with incomplete medical records or unable to undergo peripheral vascular assessment.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sohag faculty Sohag Egypt

More Sohag University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07179211 on ClinicalTrials.gov ↗ ← All trials in Egypt